TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-31

Study Completion Date

2023-03-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of TAS-117 in patients with advanced or metastatic solid tumors (excluding primary brain tumors) harboring germline PTEN inactivating mutations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

NCT02301117

Advanced Solid Tumors

COMPLETED PHASE1

A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors

NCT02025803

Neoplasms

COMPLETED PHASE1

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

NCT01449370

Metastatic Solid Tumors

COMPLETED PHASE1

Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor

NCT02601274

Cancer

TERMINATED PHASE1

PRO1107 in Patients With Advanced Solid Tumors

NCT06171789

Endometrial Cancer Ovarian Cancer Triple Negative Breast Cancer +3 more

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study TAS-117-201 is an open-label, single-arm Phase 2 study evaluating the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of TAS-117 in patients with advanced or metastatic solid tumors harboring germline PTEN inactivating mutations. The study will be conducted in two parts:

* Part A: Safety lead-in (Dose Escalation and Dose Regimen Confirmation)
* Part B: Single-arm Phase 2 study

Patients will receive TAS-117 orally every day or intermittently on a 21-day cycle

* Part A (Dose Escalation): up to 36 adult patients with advanced or metastatic solid tumors (excluding primary brain tumors) irrespective of gene alterations. The Dose Escalation consists of 2 cohorts: Daily Dose Regimen and Intermittent Dose Regimen.
* Part A (Dose Regimen Confirmation): approximately 6 adult or adolescent patients with advanced or metastatic solid tumors (excluding primary brain tumors) harboring germline PTEN inactivating mutations
* Part B (Phase 2): approximately 54 adult or adolescent patients with advanced or metastatic solid tumors (excluding primary brain tumors) harboring germline PTEN inactivating mutations

Treatment will continue until disease progression, unacceptable toxicity, or any other of the criteria for treatment discontinuation is met. For patients who discontinue treatment for reasons other than disease progression, tumor assessments should be continued until radiologic disease progression is documented or until initiation of subsequent new anticancer therapy (whichever occurs first).

Patients will be followed for survival every 12 weeks (±2 weeks) until survival events (deaths) have been reported for 75% of enrolled patients or the study is terminated early by the Sponsor.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAS-117 Dose Escalation Daily Dose Regimen (Part A: safety lead-in)

Advanced or metastatic solid tumors irrespective of gene alterations

Group Type EXPERIMENTAL

TAS-117

Intervention Type DRUG

TAS-117 will be dosed orally every day on a 21-day cycle

TAS-117 Dose Escalation Intermittent Dose Regimen (Part A: safety lead-in)

Advanced or metastatic solid tumors irrespective of gene alterations

Group Type EXPERIMENTAL

TAS-117

Intervention Type DRUG

TAS-117 will be dosed intermittently on a 21-day cycle

TAS-117 Dose and Regimen Confirmation (Part A: safety lead-in)

Advanced or metastatic solid tumors with germline PTEN inactivating mutations

Group Type EXPERIMENTAL

TAS-117

Intervention Type DRUG

TAS-117 will be dosed orally every day or intermittently on a 21-day cycle

TAS-117 Phase 2 (Part B)

Advanced or metastatic solid tumors with germline PTEN inactivating mutations

Group Type EXPERIMENTAL

TAS-117

Intervention Type DRUG

TAS-117 will be dosed orally every day or intermittently on a 21-day cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAS-117

TAS-117 will be dosed orally every day on a 21-day cycle

Intervention Type DRUG

TAS-117

TAS-117 will be dosed intermittently on a 21-day cycle

Intervention Type DRUG

TAS-117

TAS-117 will be dosed orally every day or intermittently on a 21-day cycle

Intervention Type DRUG

TAS-117

TAS-117 will be dosed orally every day or intermittently on a 21-day cycle

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
2. Dose Escalation in Part A

1. ≥18 years of age.
2. Histologically or cytologically confirmed advanced or metastatic solid tumors
3. Has progressed after standard treatment for advanced or metastatic disease or was intolerant to or ineligible for available standard therapies.
4. Patients with solid tumors irrespective of gene alterations.
5. Patients with at least one measurable or non-measurable lesion per RECIST1.1
3. Dose and Regimen Confirmation in Part A and Phase 2 (Part B)

1. ≥12 years of age. Patients age ≥12 and \<18 years must have a body weight of ≥40 kg.
2. Histologically confirmed advanced or metastatic solid tumors.
3. Has progressed after standard treatment for advanced or metastatic disease or was intolerant or ineligible to available standard therapies.
4. Patients with locally confirmed germline PTEN inactivating mutations determined from a blood sample.
5. Patients with at least one measurable lesion per RECIST 1.1.

Exclusion Criteria

1. History or current evidence of interstitial lung disease that requires steroid medication.
2. Current evidence of diabetes mellitus that requires insulin therapy.
3. Prior treatment with PI3K/AKT/mTOR pathway inhibitors.
4. Patients with primary brain tumor.
5. Patients with meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, or symptomatic or unstable brain metastasis.
6. Currently receiving chronic corticosteroid therapy of ≥10 mg/day of prednisone or its equivalent.

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No